Imaging of tumour response to immunotherapy

Kim R, Emi M, Tanabe K (2017) Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1–14. https://doi.org/10.1111/j.1365-2567.2007.02587.x Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026 Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS (2018) Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer 6:140. https://doi.org/10.1186/s40425-018-0458-z Andtbacka RH, Kaufman HL, Collichio F et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:2780–2788. https://doi.org/10.1200/JCO.2014.58.3377 Raman SS, Hecht JR, Chan E (2019) Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy 11:705–723. https://doi.org/10.2217/imt-2019-0033 Hollingsworth RE, Jansen K (2019) Turning the corner on therapeutic cancer vaccines. NPJ Vaccines 4:7. https://doi.org/10.1038/s41541-019-0103-y Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138–147. https://doi.org/10.1016/s0952-7915(03)00015-3 Bol KF, Schreibelt G, Rabold K et al (2019) The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. J Immunother Cancer 7:109. https://doi.org/10.1186/s40425-019-0580-6 Pilon-Thomas S, Kuhn L, Ellwanger S et al (2012) Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 35:615–620. https://doi.org/10.1097/CJI.0b013e31826e8f5f Prasad V (2018) Immunotherapy: tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol 15:11–12. https://doi.org/10.1038/nrclinonc.2017 Jackson HJ, Rafiq S, Brentjens RJ (2016) Driving CAR T-cells forward. Nat Rev Clin Oncol 13:370–383. https://doi.org/10.1038/nrclinonc.2016.36 Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8:1069–1086. https://doi.org/10.1158/2159-8290.CD-18-0367 Approved immunotherapies. Medi paper available from: https://medi-paper.com/us-fda-approved-immune-checkpoint-inhibitors-approved-immunotherapies/. Accessed Oct 26, 2019 Madan RA, Gulley JL, Fojo T, Dahut WL (2010) Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 15:969–975. https://doi.org/10.1634/theoncologist.2010-0129 Kaech SM, Wherry EJ, Ahmed R (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2:251–262. https://doi.org/10.1038/nri778 Xiang R, Lode HN, Gillies SD, Reisfeld RA (1999) T cell memory against colon carcinoma is long-lived in the absence of antigen. J Immunol 163:3676–3683 Wolchok JD, Hoos A, O'Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420. https://doi.org/10.1158/1078-0432.CCR-09-1624 Larkin J, Minor D, D'Angelo S et al (2018) Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol 36:383–390. https://doi.org/10.1200/JCO.2016.71.8023 Robert C, Ribas A, Hamid O et al (2018) Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 36:1668–1674. https://doi.org/10.1200/JCO.2017.75.6270 Horn L, Spigel DR, Vokes EE et al (2017) Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35:3924–3933. https://doi.org/10.1200/JCO.2017.74.3062 Haslam A, Prasad V (2019) Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2:e192535. https://doi.org/10.1001/jamanetworkopen.2019.2535 Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297–1306. https://doi.org/10.1007/s00262-008-0642-y Gainor JF, Longo DL, (2014) Chabner BA (2014) Pharmacodynamic biomarkers: falling short of the mark? Clin Cancer Res 20:2587–2594. https://doi.org/10.1158/1078-0432.CCR-13-3132 Nishino M, Giobbie-Hurder A, Manos MP et al (2017) Immune-related tumor response dynamics in melanoma patients (pts) treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions. Clin Cancer Res 23: 4671–4679. https://doi.org/10.1158/1078-0432.CCR-17-0114 Thust SC, van den Bent MJ, Smits M (2018) Pseudoprogression of brain tumors. J Magn Reson Imaging 48:571–589. https://doi.org/10.1002/jmri.26171 Hodi FS, Hwu WJ, Kefford R et al (2016) Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34:1510–1517. https://doi.org/10.1200/JCO.2015.64.0391 Fujimoto D, Yoshioka H, Kataoka Y et al (2019) Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy. J Thorac Oncol 14:468–474. https://doi.org/10.1016/j.jtho.2018.10.167 Champiat S, Ferrara R, Massard C et al (2018) Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 15:748–762. https://doi.org/10.1038/s41571-018-0111-2 Ferrara R, Mezquita L, Texier M et al (2018) Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 4:1543–1552. https://doi.org/10.1001/jamaoncol.2018.3676 Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID (2008) The effects of surgery on tumor growth: a century of investigations. Ann Oncol 19:1821–1828. https://doi.org/10.1093/annonc/mdn386 Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F (2012) Radiation-induced reprogramming of breast cancer cells. Stem Cells 30:833–844. https://doi.org/10.1002/stem.1058 Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214. https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS (2013) Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 19:3936–3943. https://doi.org/10.1158/1078-0432.CCR-13-0895 Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143–e152. https://doi.org/10.1016/S1470-2045(17)30074-8 Hodi FS, Ballinger M, Lyons B et al (2018) Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol 36:850–858. https://doi.org/10.1200/JCO.2017.75.1644 Kataoka Y, Hirano K (2018) Which criteria should we use to evaluate the efficacy of immune-checkpoint inhibitors? Ann Transl Med 6:222. https://doi.org/10.21037/atm.2018.04.17 Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168. https://doi.org/10.1056/NEJMra1703481 Haanen JBAG, Carbonnel F, Robert C et al (2018) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv264–iv266. https://doi.org/10.1093/annonc/mdy162 Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563–580. https://doi.org/10.1038/s41571-019-0218-0 Wang PF, Chen Y, Song SY et al (2017) Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol 8:730. https://doi.org/10.3389/fphar.2017.00730 Sun X, Roudi R, Dai T et al (2019) Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer 19:558. https://doi.org/10.1186/s12885-019-5701-6 Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13:211. https://doi.org/10.1186/s12916-015-0455-8 Nishino M, Hatabu H, Hodi FS (2019) Imaging of cancer immunotherapy: current approaches and future directions. Radiology 290:9–22. https://doi.org/10.1148/radiol.2018181349 Bronstein Y, Ng CS, Hwu P, Hwu WJ (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197:W992–w1000. https://doi.org/10.2214/AJR.10.6198 Carter BW, Halpenny DF, Ginsberg MS, Papadimitrakopoulou VA, de Groot PM (2017) Immunotherapy in non-small cell lung cancer treatment: current status and the role of imaging. J Thorac Imaging 32:300–312. https://doi.org/10.1097/RTI.0000000000000291 Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA (2015) Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics 35:424–437. https://doi.org/10.1148/rg.352140121 Tirumani SH, Ramaiya NH, Keraliya A et al (2015) Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3:1185–1192. https://doi.org/10.1158/2326-6066.CIR-15-0102 Wang GX, Kurra V, Gainor JF et al (2017) Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings. Radiographics 37:2132–2144. https://doi.org/10.1148/rg.2017170085 Gupta A, De Felice KM, Loftus EV Jr, Khanna S (2015) Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 42:406–417. https://doi.org/10.1111/apt.13281 Alessandrino F, Sahu S, Nishino M et al (2019) Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdom Radiol (NY) 44:1917–1927. https://doi.org/10.1007/s00261-019-01935-2 Kim KW, Ramaiya NH, Krajewski KM et al (2013) Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31:1071–1077. https://doi.org/10.1007/s10637-013-9939-6 Raad RA, Pavlick A, Kannan R, Friedman KP (2015) Ipilimumab-induced hepatitis on 18F-FDG PET/CT in a patient with malignant melanoma. Clin Nucl Med 40:258–259. https://doi.org/10.1097/RLU.0000000000000606 Alabed YZ, Aghayev A, Sakellis C, Van den Abbeele AD (2014) Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET/CT. Clin Nucl Med 40:e528–e529. https://doi.org/10.1097/RLU.0000000000000940 Faje AT, Sullivan R, Lawrence D et al (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99:4078–4085. https://doi.org/10.1210/jc.2014-2306 Alessandrino F, Shah HJ, Ramaiya NH (2018) Multimodality imaging of endocrine immune related adverse events: a primer for radiologists. Clin Imaging 50:96–103. https://doi.org/10.1016/j.clinimag.2017.12.014 Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR (2009) Ipilimumab-induced hypophysitis: MR imaging findings. AJNR Am J Neuroradiol 30:1751–1753. https://doi.org/10.3174/ajnr.A1623 Solinas C, Porcu M, De Silva P et al (2018) Cancer immunotherapy-associated hypophysitis. Semin Oncol 45:181–186. https://doi.org/10.1053/j.seminoncol.2018.09.002 Lee H, Hodi FS, Giobbie-Hurder A et al (2017) Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy. Cancer Immunol Res 5:1133–1140. https://doi.org/10.1158/2326-6066.CIR-17-0208 Bacanovic S, Burger IA, Stolzmann P, Hafner J, Huellner MW (2015) Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET/CT. Clin Nucl Med 40:e518–e519. https://doi.org/10.1097/RLU.0000000000000887 Chuzi S, Tavora F, Cruz M et al (2017) Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res 9:207–213. https://doi.org/10.2147/CMAR.S136818 Naidoo J, Wang X, Woo KM et al (2017) Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 35:709–717. https://doi.org/10.1200/JCO.2016.68.2005 Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS (2016) Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2:1607–1616. https://doi.org/10.1001/jamaoncol.2016.2453 Khunger M, Rakshit S, Pasupuleti V et al (2017) Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 152:271–281. https://doi.org/10.1016/j.chest.2017.04.177 Nishino M, Ramaiya NH, Awad MM et al (2016) PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 22:6051–6060. https://doi.org/10.1158/1078-0432.CCR-16-1320 Delaunay M, Cadranel J, Lusque A et al (2017) Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 10:50. https://doi.org/10.1183/13993003 Montaudié H, Pradelli J, Passeron T, Lacour JP, Leroy S (2017) Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol 176:1060–1063. https://doi.org/10.1111/bjd.14808 Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749–1755. https://doi.org/10.1056/NEJMoa1609214 Loffler AI, Salerno M (2018) Cardiac MRI for the evaluation of oncologic cardiotoxicity. J Nucl Cardiol 25:2148–2158. https://doi.org/10.1007/s12350-018-1293-9 Altan M, Toki MI, Gettinger SN et al (2019) Immune checkpoint inhibitor-associated pericarditis. J Thorac Oncol 14:1102–1108. https://doi.org/10.1016/j.jtho.2019.02.026 Crout TM, Lennep DS, Kishore S, Majithia V (2019) Systemic vasculitis associated with immune check point inhibition: analysis and review. Curr Rheumatol Rep 21:28. https://doi.org/10.1007/s11926-019-0828-7 Psimaras D (2018) Neuromuscular complications of immune checkpoint inhibitors. Presse Med 47:e253–e259. https://doi.org/10.1016/j.lpm.2018.10.009 Gandhi L, Rodríguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092. https://doi.org/10.1056/NEJMoa1801005 Meléndez B, Van Campenhout C, Rorive S, Remmelink M, Salmon I, D'Haene N (2018) Methods of measurement for tumor mutational burden in tumor tissue. Transl Lung Cancer Res 7:661–667. https://doi.org/10.21037/tlcr.2018.08.02 Samstein RM, Lee CH, Shoushtari AN et al (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51:202–206. https://doi.org/10.1038/s41588-018-0312-8 Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409–413. https://doi.org/10.1126/science.aan6733 Salem ME, Puccini A, Grothey A et al (2018) Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Mol Cancer Res 16:805–812. https://doi.org/10.1158/1541-7786 Oble DA, Loewe R, Yu P, Mihm MC Jr (2009) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 9:3. PMCID: PMC2935762 Romagnoli G, Wiedermann M, Hübner F et al (2017) Morphological evaluation of tumor-infiltrating lymphocytes (TILs) to investigate invasive breast cancer immunogenicity, reveal lymphocytic networks and help relapse prediction: a retrospective study. Int J Mol Sci 18:pii: E1936. doi: https://doi.org/10.3390/ijms18091936 Kwak Y, Koh J, Kim DW, Kang SB, Kim WH, Lee HS (2016) Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. Oncotarget 7:81778–81790. https://doi.org/10.18632/oncotarget.13207 Sun R, Limkin EJ, Vakalopoulou M et al (2018) A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 19:1180–1191. https://doi.org/10.1016/S1470-2045(18)30413-3 Heskamp S, Hobo W, Molkenboer-Kuenen JD et al (2015) Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies. Cancer Res 75:2928–2936. https://doi.org/10.1158/0008-5472.CAN-14-3477 Chatterjee S, Lesniak WG, Gabrielson M et al (2016) A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget 7:10215–10227. https://doi.org/10.18632/oncotarget.7143 Bensch F, van der Veen EL, Lub-de Hooge MN et al (2018) (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med 24:1852–1858. https://doi.org/10.1038/s41591-018-0255-8 Gettinger SN, Horn L, Gandhi L et al (2015) Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 33:2004–2012. https://doi.org/10.1200/JCO.2014.58.3708 Nishino M, Dahlberg SE, Adeni AE et al (2017) Tumor response dynamics of advanced non-small cell lung cancer patients treated with PD-1 inhibitors: imaging markers for treatment outcome. Clin Cancer Res 23:5737-5744. https://doi.org/10.1158/1078-0432.CCR-17-1434 Katz SI, Hammer M, Bagley SJ et al (2018) Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 13:978-986. https://doi.org/10.1016/j.jtho.2018.04.010.